Skip to main content
SpringerLink
Log in

High Prevalence and Undertreatment of Hypercholesterolaemia in Participants in a Public Stroke Prevention Programme in Austria

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background: There is remarkable consistency in large cohort studies regarding the relationship between serum cholesterol and the incidence of coronary heart disease (CHD), and increasing interest in the relationship between serum cholesterol and stroke. The aim of our investigation was to identify the prevalence and control of hypercholesterolaemia in participants in a public stroke prevention programme.

Patients and methods: 9274 participants were categorised according to the guidelines of the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) and analysed with reference to risk category, treatment eligibility and treatment quality.

Results: NCEP-ATP III identifies low-density lipoprotein (LDL) cholesterol as the primary target of treatment. In this programme, 499 (5.4%) subjects were classified as having optimal (<100 mg/dL) LDL cholesterol levels, 1718 (18.5%) as near optimal (100–129 mg/dL), 2863 (30.9%) as borderline high (130–159 mg/dL), 2472 (26.7%) as high (160–189 mg/dL) and 1722 (18.6%) as very high (>190 mg/dL). 4442 (47.9%) participants presented with 0–1 risk factors, 2451(26.4%) with multiple (2+) risk factors, and 2381 (25.7%) met the criteria of secondary prevention. The suggested treatment goals were met in 2411 (54.3%) participants with 0–1 risk factors, in 561 (22.9%) of the multiple-risk-factor group, and in 148 (6.2%) subjects with established CHD or risk equivalents. A total of 871 subjects (9.4%) reported use of cholesterol-lowering drugs.

Conclusions: We observed a considerable prevalence and poor control of hypercholesterolaemia in participants in a public stroke prevention programme in Austria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Mackay J, Mensah G, editors. Atlas of heart disease and stroke. Geneva: World Health Organisation, 2004 [online]. Available from URL: http://www.who.int/cardiovascular_diseases/resources/atlas/en/print.html [Accessed 2005 May 23]

    Google Scholar 

  2. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations. BMJ 1991; 303: 276–82

    Article  PubMed  CAS  Google Scholar 

  3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9

    Google Scholar 

  4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7

    Article  PubMed  CAS  Google Scholar 

  5. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57

    Article  Google Scholar 

  6. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial —Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58

    Article  PubMed  CAS  Google Scholar 

  7. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease? BMJ 1994; 308: 367–72

    Article  PubMed  CAS  Google Scholar 

  8. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet 1995; 346: 1647-53

    Google Scholar 

  9. Lindenstroem E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol and triglycerides on the risk of cerebrovascular disease: The Copenhagen City Heart Study. BMJ 1994; 309: 11–5

    Article  Google Scholar 

  10. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001; 103: 387–92

    Article  PubMed  CAS  Google Scholar 

  11. Crouse III JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455–9

    Article  PubMed  Google Scholar 

  12. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577–81

    Article  PubMed  CAS  Google Scholar 

  13. O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14–22

    Article  PubMed  Google Scholar 

  14. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151: 478–87

    Article  PubMed  CAS  Google Scholar 

  15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22

    Article  Google Scholar 

  16. Di Napoli P, Taccardi AA, Oliver M, et al. Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J 2002; 23: 1908–21

    Article  PubMed  Google Scholar 

  17. Iglseder B, Moroder T, Staffen W, et al. Inadequate management of cerebrovascular risk factors in participants of a public stroke prevention program in Austria. Eur J Neurol 2004; 11: 679–85

    Article  PubMed  CAS  Google Scholar 

  18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Adult Treatment Panel III. JAMA 2001; 285: 2486-2497

    Google Scholar 

  19. Wolf PA, D’Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22: 312–8

    Article  PubMed  CAS  Google Scholar 

  20. American Diabetes Association. New recommendations about the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1138–95

    Article  Google Scholar 

  21. Mosca L, Jones WK, King KB, et al. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States. Arch Fam Med 2000; 9: 506–15

    Article  PubMed  CAS  Google Scholar 

  22. Kahl H, Hölling H, Kamtsiuris P. Inanspruchnahme von Früherkennungsuntersuchungen und Maβnahmen zur Gesundheitsförderung. Gesundheitswesen 1999; 61Suppl. 2: 163–8

    Google Scholar 

  23. Meagher EA. Addressing cardiovascular disease in women: focus on dyslipidemia. J Am Board Fam Pract 2004; 17: 424–37

    Article  PubMed  Google Scholar 

  24. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross section survey. BMJ 2000; 321: 1322–5

    Article  PubMed  CAS  Google Scholar 

  25. Whincup PH, Emberson JR, Lennon L, et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 2002; 88: 25–9

    Article  PubMed  CAS  Google Scholar 

  26. Oliver MF. Might treatment of hypercholesterolemia increase non-cardiac mortality? Lancet 1991; 337: 1529–31

    Article  PubMed  CAS  Google Scholar 

  27. Wallis E, Ramsay LE, Haq IU. Coronary and cardiovascular risk estimation: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000; 320: 671–6

    Article  PubMed  CAS  Google Scholar 

  28. Pickin DM, McCabe CJ, Ramsey LE. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999; 82: 325–32

    PubMed  CAS  Google Scholar 

  29. van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J 2001; 22(9): 751–61

    Article  PubMed  Google Scholar 

  30. Ballesteros LC, Fernandez San Martin MI, Sanz Cuesta T, et al. The cost of inadequate prescriptions for hypolipidemic drugs. VICAF Group. Pharmacoeconomics 2001; 19: 513–22

    Article  PubMed  CAS  Google Scholar 

  31. Austrian Atherosclerosis Society (AAS). Cholesterinkonsensus 2000 [online]. Available from URL: www.aas.at [Accessed 2005 Aug 16]

  32. Mantel-Teeuwisse AK, Verschuren WMM, Klungel OH, et al. Recent trends in (under)treatment of hypercholesterolemia in the Netherlands. Br J Clin Pharmacol 2004; 58: 310–6

    Article  PubMed  Google Scholar 

  33. Monkman D. Treating dyslipidaemia in primary care. BMJ 2000; 32: 1299–300

    Article  Google Scholar 

  34. Denke MA. Cholesterol-lowering diets: a review of the evidence. Arch Intern Med 1995; 155: 17–26

    Article  PubMed  CAS  Google Scholar 

  35. Brunner E, Cohen D, Toon L. Cost effectiveness of cardiovascular disease prevention strategies: a perspective on EU food based dietary guidelines. Public Health Nutr 2001; 4: 711–5

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Mynda Schreuer, PhD, University of Salzburg, for the statistical review. The Salzburg Stroke Prevention Program is supported by grants from the Bundesland Salzburg and the Gebietskrankenkasse Salzburg.

The authors have no potential conflicts of interest that are directly relevant to the contents of this article.

Author information

Authors and Affiliations

  1. Department of Neurology, Christian Doppler Klinik and Paracelsus Private Medical University Salzburg, Ignaz-Harrer-Strasse 79, A-5020, Salzburg, Austria

    Bernhard Iglseder, Titus Moroder, Wolfgang Staffen & Gunther Ladurner

Authors
  1. Bernhard Iglseder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Titus Moroder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wolfgang Staffen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gunther Ladurner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernhard Iglseder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iglseder, B., Moroder, T., Staffen, W. et al. High Prevalence and Undertreatment of Hypercholesterolaemia in Participants in a Public Stroke Prevention Programme in Austria. Clin. Drug Investig. 25, 709–717 (2005). https://doi.org/10.2165/00044011-200525110-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200525110-00004

Keywords

Search

Navigation